爬一下新聞有兩家
1. NHK，我看不懂日文所以看英文
https://tinyurl.com/f9wfh4ax
"So Daiichi Sankyo is considering holding the trial in a noninferiority-test
format to confirm that its vaccine can produce antibodies in acceptable
amounts compared to other vaccines already in use."
似乎確實有考慮免疫橋接(用抗體來比較)
2. 日經，我也是看英文
https://tinyurl.com/pkhsvxd6
"So Daiichi Sankyo's next trial is expected to test non-inferiority, meaning
that the goal is to show the company's new treatment matches or outperforms
those made by Pfizer and Moderna